Last reviewed · How we verify

NCT06555861: MUMOFRAT retro

Local Recurrence Prediction of by Texture Analysis Derived From Positron Emission Tomography (PET / CT) Imaging of Non-small Cell Lung Cancer (NSCLC) Treated With Stereotactic Radiotherapy (SBRT) (Retros MUMOFRAT)

Completed Last updated 15 August 2024
What this trial tests

trial in Identify FDG PET/CT Parameters Predictive of Local Control in 87 participants. Completed in 6 February 2019.

Timeline
7 January 2019
Primary endpoint
6 February 2019
6 February 2019

Quick facts

Lead sponsorUniversity Hospital, Brest
StatusCompleted
Study typeOBSERVATIONAL
Enrollment87
Start date7 January 2019
Primary completion6 February 2019
Estimated completion6 February 2019
Sites4 locations across France

Conditions studied

Sponsor

University Hospital, Brest

Who can join

18 and older, any sex, with Identify FDG PET/CT Parameters Predictive of Local Control. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this retrospective multicentric study was to develop and evaluate a prognostic FDG PET/CT radiomics signature in early-stage non-small cell lung cancer (NSCLC) patients treated with stereotactic radiotherapy (SBRT).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Brest trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06555861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing